PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
14-Dec-2022 PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares PAION AG
14-Dec-2022 Cantourage Group SE: Most potent cannabis flower on the German market: Cantourage launches Miracle Valley’s second product Cantourage Group SE
14-Dec-2022 Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept Apogenix AG
14-Dec-2022 STORM Therapeutics announces closing of USD $30M Series B financing STORM Therapeutics
14-Dec-2022 Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases Poolbeg Pharma
14-Dec-2022 Evolva launches its Natural Nootkatone Evolva Holding SA
14-Dec-2022 Relief Therapeutics to Participate in January Investor Meetings Relief Therapeutics Holding SA
14-Dec-2022 Cosmo announces successful Phase III clinical trial of Lumeblue™ in China Cosmo Pharmaceuticals N.V.
14-Dec-2022 Epigenomics Releases Performance Data on Next Generation Test Epigenomics AG
14-Dec-2022 Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test Epigenomics AG
14-Dec-2022 Epigenomics Releases Performance Data on Next Generation Test Epigenomics AG
13-Dec-2022 Scottish Medicines Consortium (SMC) Extends Advice Accepting RINVOQ®▼(upadacitinib) For Treatment of Adults with Moderate Rheumatoid Arthritis AbbVie
13-Dec-2022 Glenmark’s antimalarial wins Highly Commended at Pharmacy MVP Awards Glenmark
13-Dec-2022 DAVID BROCKLEHURST APPOINTED HEAD OF ONCOLOGY AT ASTRAZENECA UK AstraZeneca
13-Dec-2022 Risk of complications and comorbidity higher in South Asian and Black cancer patients compared with population averages across England1 Janssen Pharmaceutical Companies of Johnson & Johnson
13-Dec-2022 Catch Up With PHARMAP 2023: Pharmaceutical Challenges And Strategies PHARMAP 2023
13-Dec-2022 Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Janssen
13-Dec-2022 1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors 1ST Biotherapeutics, Inc.
13-Dec-2022 Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas Spexis AG
13-Dec-2022 Relief Therapeutics Announces Issuance of Shares from Authorized Capital Relief Therapeutics Holding SA